{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"69.0","upperLimit":"87.1","value":"79.1"},{"groupId":"OG001","lowerLimit":"41.9","upperLimit":"91.6","value":"71.4"}]}],"title":"After 4 Cycles of Induction"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"78.3","upperLimit":"93.4","value":"87.2"},{"groupId":"OG001","lowerLimit":"49.2","upperLimit":"95.3","value":"78.6"}]}],"title":"At the End of Induction"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"81.1","upperLimit":"95.1","value":"89.5"},{"groupId":"OG001","lowerLimit":"57.2","upperLimit":"98.2","value":"85.7"}]}],"title":"At the End of Maintenance"}],"denoms":[{"counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"14"}],"units":"Participants"}],"description":"ORR: percentage of participants achieved PR or better (PR,VGPR,CR,sCR) per IMWG. CR:negative immunofixation on serum, urine, disappearance of soft tissue plasmacytomas,\\<5% PCs in bone marrow(BM). sCR:CR plus normal FLC ratio,absence of clonal cells in BM by immunohistochemistry, immunofluorescence. VGPR:Serum, urine M-protein detectable by immunofixation but not on electrophoresis or \\>=90% reduction in serum M-protein plus urine M-protein level \\<100 mg/24hours. PR:\\>=50% reduction of serum M-protein and reduction in 24hours urinary M-protein by \\>=90% or to \\<200mg/24hours. If serum, urine M-protein unmeasurable, a\\>=50% decrease in difference involved and uninvolved FLC levels required in place of M-protein criteria. If serum, urine M-protein not measurable, serum free light assay is not measurable,\\>=50% reduction in PCs required in place of M-protein,provided baseline bone marrow PCs% \\>=30%, if present at baseline, a \\>=50% reduction in size of soft tissue plasmacytomas is also required.","dispersionType":"95% Confidence Interval","groups":[{"description":"Induction therapy:Participants received daratumumab, cyclophosphamide, bortezomib, and dexamethasone (Dara-CyBorD) as: daratumumab 8 mg/kg IV on Cycle 1(Day 1,2) and 16 mg/kg IV on Cycle 1(Days 8,15,22), Cycle 2 (Days 1,8,15,22), Cycles 3-6 (Days 1,15), Cycles 7-8(Day 1); Cyclophosphamide 300 mg/m\\^2 orally on Days 1,8,15,22 of each cycle (28 days); Bortezomib 1.5 mg/m\\^2 SC on Days 1,8,15 of each cycle; Dexamethasone 20 mg IV on Cycle 1(Day1,2,8,15,22) and orally on Cycle 1(Day 9,16,23), 40 mg IV or oral on Cycle 2 (Days 1,8,15,22), Cycle 3-8 (\\[if with CyBorD\\] Days 1,8,15,22). Consolidation therapy (CT):Participants who were considered eligible for transplant underwent autologous stem cell transplantation \\[ASCT\\] at investigator discretion. Maintenance therapy:Daratumumab 16 mg/kg IV on Day 1 for 12 cycles or until PD, whichever occurred first; Dexamethasone 12 mg IV or oral on Day 1 of each cycle(for ASCT participants, maintenance therapy was to begin approximately 90 days after ASCT).","id":"OG000","title":"Newly Diagnosed Multiple Myeloma (NDMM)"},{"description":"Participants with RMM (defined as having achieved at least a PR with first-line therapy before progression) received treatment as-Induction therapy:Participants received Dara-CyBorD as: daratumumab 8 mg/kg IV on Cycle 1(Day 1,2) and 16 mg/kg IV on Cycle 1(Days 8,15,22),Cycle 2 (Days 1,8,15,22),Cycles 3-6(Days 1,15),Cycles 7-8(Day 1); Cyclophosphamide 300 mg/m\\^2 orally on Days 1,8,15,22 of each cycle (28 days); Bortezomib 1.5 mg/m\\^2 SC on Days 1,8,15 of each cycle; Dexamethasone 20 mg IV on Cycle 1(Day1,2,8,15,22) and orally on Cycle 1(Day 9,16,23), 40 mg IV or oral on Cycle 2(Days 1,8,15,22),Cycle 3-8 (\\[if with CyBorD\\] Days 1,8,15,22). CT: Participants who were considered eligible for transplant underwent ASCT at investigator discretion. Maintenance therapy:Daratumumab 16 mg/kg IV on Day 1 for 12 cycles or until PD, whichever occurred first; Dexamethasone 12 mg IV or oral on Day 1 of each cycle(for ASCT participants, maintenance therapy was to begin approximately 90 days after ASCT).","id":"OG001","title":"Relapsed Multiple Myeloma (RMM)"}],"paramType":"NUMBER","populationDescription":"Response-evaluable set includes all enrolled participants who had measurable disease, received at least 1 dose of study treatment, and had at least 1 efficacy evaluation assessment.","reportingStatus":"POSTED","timeFrame":"After 4 Cycles of Induction (4 months), at End of Induction (4 to 8 months) and at the End of Maintenance (12 months)","title":"Overall Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}